Crohn's disease biologics comparison

Gastroenterology

Compare biologic and targeted therapies for moderate-to-severe Crohn's disease. TNF inhibitors were the first biologics for Crohn's; newer options include IL-23 inhibitors, integrin inhibitors, and JAK inhibitors.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
RemicadeJanssenIV infusionEvery 8 weeks (after loading)First biologic for Crohn's; biosimilars preferred by payers; proven fistula data
HumiraAbbVieSC injectionEvery 2 weeksSC TNF inhibitor; biosimilars available; most prescribed
StelaraJanssenIV induction → SC maintenanceEvery 8 weeks (after IV induction)IL-12/23 inhibitor; IV induction, SC maintenance; biosimilars available
EntyvioTakedaIV infusion or SC injectionEvery 8 weeks (IV) or every 2 weeks (SC)Gut-selective integrin inhibitor; favorable safety profile; SC option
SkyriziAbbVieIV induction → SC maintenanceEvery 8 weeks (after IV induction)IL-23 inhibitor; high endoscopic response rates; newer for Crohn's
CimziaUCBSC injectionEvery 4 weeks (after loading)PEGylated TNFi; preferred in pregnancy (no active placental transfer)
TysabriBiogenIV infusionEvery 4 weeksIntegrin inhibitor; high efficacy; PML risk requires JCV monitoring
RinvoqAbbVieOral (tablet)DailyOral JAK inhibitor; black-box warning limits positioning

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.